Aayush Food And Herbs Ltd Directors Report

To,

The Members of Aayush Wellness Limited,

(Formerly known as Aayush Food and Herbs Limited)

The Board are pleased to present the 41th Annual Report of the company together with the Audited Financial Statement for the financial year ended as on March 31, 2025.

FINANCIAL INFORMATION:

(All amounts in INR Lakhs)

Particulars	Standalone		Consolidated
	2024-25	2023-24	2024-25	2023-24
Revenue from Operations and Other	7338.60	83.92	7338.60	83.92
Income
Expenses	7001.11	24.69	7001.11	24.69
Profit (Loss) before Exceptional and	337.49	59.23	337.49	59.23
Extra Ordinary Items and Tax
Less: Exceptional Items	-	-	-	-
Less: Extra Ordinary Items	-	-	-	-
Profit before Tax	337.49	59.23	337.49	59.23
Less: Current Tax	9.00	0.99	9.00	0.99
Less: Deferred Tax Liability	8.10	1.05	8.10	1.05
Profit after Taxation	336.58	57.18	336.58	57.18

REVIEW OF OPERATIONS:

During the year under review, gross annual revenue stands at Rs. 7338.60 lakhs as compared to Rs. 83.92 lakhs for previous year. Profit before tax stands at Rs. 337.49 lakhs as compared to Profit of Rs. 59.23 lakhs in previous year. Profit after tax stands at Rs. 336.58 lakhs as compared to Profit of Rs. 57.18 lakhs in previous year.

DIVIDEND:

During Financial year 2024-25, your Company paid an interim dividend of Rs. 0.01/- (One paisa only) per equity share having face value of Re. 01/- (Rupee One only) each, for the quarter ended December 31, 2024.

Further Board of Directors at their meeting held on July 30, 2025 declared interim dividend of Rs. 0.025/- (Two and half paisa only) per equity share having face value of Re. 01/- (Rupee One only) each, for the quarter ended June 30, 2025.

TRANSFER TO RESERVES:

The Company did not transfer any amount to Reserves during the year under consideration.

SHARE CAPITAL:

Authorized Share Capital:

The Authorized Share Capital of the Company as on March 31, 2025, stood at Rs. 9,00,00,000/- (Rupees Nine Crores Only) divided into 9,00,00,000 (Nine Crores) equity shares of Rs. 01/- (Rupees One) each.

During the year, the Company enhanced its Authorized Share Capital in two phases

- From Rs. 3,50,00,000/- (Rupees Three Crores Fifty Lakhs only) to Rs. 7,00,00,000/- (Rupees Seven Crores only), pursuant to the approval of shareholders by way of Special Resolution passed through postal ballot on July 23, 2024.

- Subsequently, from Rs. 7,00,00,000/- (Rupees Seven Crores only) to Rs. 9,00,00,000/- (Rupees Nine Crores only), through a Special Resolution passed via postal ballot on October 29, 2024.

Issued, Subscribed and Paid-up Capital:

The Issued, Subscribed, and Paid-up Equity Share Capital of the Company as on March 31, 2025, stood at Rs. 4,86,71,699/- Rupees Four Crore Eighty-Six Lakh Seventy-One Thousand Six Hundred and Ninety-Nine only, comprising 4,86,71,699 (Four Crore Eighty-Six Lakh Seventy-One Thousand Six Hundred and Ninety-Nine) equity shares of face value 1/- (Rupee One) each.

During the year under review:

- The Board of Directors at their meeting held on June 19, 2024 approved a stock split of 1 (One) equity share of face value 10/- (Rupees Ten only) into 10 (Ten) equity shares of face value 1/- (Rupee One only) each. The same was approved by the shareholders through a Special Resolution passed via postal ballot concluded on July 23, 2024.

- At its meeting held on October 29, 2024, the Board of Directors approved and recommended the issuance of Bonus Shares in the ratio of 1:2, i.e., 1 (One) fully paid-up equity share for every 2 (Two) existing equity shares of face value 1/- each. This proposal was subsequently approved by the shareholders through an Ordinary Resolution passed via postal ballot concluded on December 01, 2024.

- In the same meeting, the Board also approved a proposal for raising funds through a Rights Issue of equity shares having face value 1/- (Rupee One only) each, for an amount not exceeding 49,90,00,000/- (Rupees Forty-Nine Crores Ninety Lakhs only).

ANNUAL RETURN:

Pursuant to Section 92(3) read with Section 134(3)(a) of the Companies Act, the Annual Return as on 31st March 2025 will be available on the Companys website with in stipulated period of time.

PUBLIC DEPOSIT:

The Company has not accepted any deposits from the public falling within the purview of Section 73 of the Act read with the Companies (Acceptance of Deposit) Rules, 2014 during the year. Neither there was any public deposit outstanding as at the beginning or end of the year ended on March 31, 2025.

SUBSIDIARIES, JOINT VENTURE OR ASSOCIATE COMPANIES:

During the year under review, the following companies has incorporated as wholly owned subsidiaries (WOS) of the Company:

Sr. No.	Name of Company	Relationship	Change	Effective Date
1.	AAYUSH HEALTHSCIENCES PRIVATE LIMITED	WOS	Incorporated	November 07, 2024
2.	AAYUSH WORLDWIDE PRIVATE LIMITED	WOS	Incorporated	January 04, 2024
3.	AAYUSH LABS PRIVATE LIMITED	WOS	Incorporated	August 26, 2025
4.	AAYUSH VENTURES PRIVATE LIMITED	WOS	Incorporated	August 27, 2025

A report containing the salient features of the subsidiaries as required under Section 129(3) of the Companies Act 2013 has been annexed herewith in AOC 1 and is attached as Annexure- 1 to this report.

The Company does not have Joint Venture or Associate Company.

RELATED PARTY TRANSACTIONS:

All Related Party Transactions that were entered into during the financial year were on an arms length basis, in the ordinary course of business and were in compliance with the applicable provisions of the Act and the Listing Regulations. There were no materially significant Related Party Transactions made by the Company during the year that would have required Shareholder approval under the Listing Regulations.

All Related Party Transactions are placed before the Audit Committee for approval. Prior omnibus approval of the Audit Committee is obtained for the transactions which are repetitive in nature, whenever required. A statement of all Related Party Transactions is placed before the Audit Committee for its review on a quarterly basis, specifying the nature, value and terms and conditions of the transactions.

Further, the details of the related party transactions as required under Section 134(3)(h) r/w Rule 8 (2) of the Companies (Accounts) Rules, 2014 and under Regulations 34(3) & 53(f) of Para A of Schedule V of SEBI (LODR) Regulations, 2015 are provided in Form AOC 2 given as Annexure 2 of Boards Report.

CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE EARNINGS AND OUTGO:

The company has made the necessary disclosures in this Report in terms of section 134 (3)(m) of the Companies Act, 2013 read with rule 8(3) of the Companies (Accounts) Rules, 2014. The company has always strived to optimize energy consumption. Details of the same is enclosed as Annexure 3.

MANAGEMENT DISCUSSION AND ANALYSIS REPORT:

In terms of the Regulation 34 read with Schedule V of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, Management Discussion and Analysis report covering details of Risks and Concerns, Internal Control Systems and their Adequacy, Discussion on Financial Managements Performance etc. for the year under review is set out in this Annual Report as Annexure 4.

CORPORATE GOVERNANCE REPORT:

Pursuant to Regulation 15 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the compliance with the corporate governance provisions as specified in Regulations 17, 17A, 18, 19, 20, 21,22, 23, 24, 24A, 25, 26, 27 and 46 and para C, D and E of Schedule V shall not apply, in respect of the listed entity having paid up equity share capital not exceeding rupees ten crores and net worth not exceeding rupees twenty five crore, as on the last day of the previous financial year.

Thus, due to non-applicability, a separate report of Corporate Governance has not been provided in this Annual report.

CORPORATE SOCIAL RESPONSIBILITY:

The conditions prescribed in the Section 135 of the Companies Act, 2013, which mandates the Company to constitute a Corporate Social Responsibility Committee are not applicable to the Company and hence it is not required to formulate policy on Corporate Social Responsibility.

PARTICULARS OF EMPLOYEES AND RELATED INFORMATION:

The information required pursuant to Section 197(12) of the Act, read with Rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 is disclosed in Annexure 5 to this report.

DIRECTORS AND KEY MANAGERIAL PERSONNEL:

The Board of the Company is optimum combination of Directors to meet the criteria as specified Regulation 17 of the SEBI LODR. The Company also have KMPs as specified under Section 203 of the Act and relevant regulations of SEBI LODR. Details of Directors and KMPs during the FY 2024-25 are as follows:

Name of the Director and KMP	Designation	Date of Appointment	Change in Designation	Date of Resignation
Dr. Lalitkumar Anande1	Chairman & Non- Executive Independent Director	February 09, 2024	June 20, 2025	-
Mr. Naveenakumar Kunjaru 2	Managing Director	June 13, 2023	June 20, 2025	-
Mr. Gavadu Patil	Non-Executive Non- Independent Director	February 09, 2024	May 03, 2024	-
Ms. Pallavi Mittal	Non-Executive Non- Independent Director	January 13, 2017	June 13, 2023	-
Ms. Vishakha Jadhav	Non-Executive Independent Director	April 17, 2023	September 30, 2023	-
Mr. Surajmal Jain	CFO	March 28, 2024	-	-
Ms. Sneha Khemka3	Company Secretary & Compliance Officer	February 01, 2025	-	-
Mrs. Sakshi Chopra4	Company Secretary & Compliance officer	August 29, 2024	-	January 31, 2025
Ms. Urmi Shah5	Company Secretary	July 22, 2023	-	August 29, 2024

Notes:

1. Dr. Lalitkumar Anande was appointed as an Additional Non-Executive Independent Director w.e.f. February 09, 2024 and regularized in the postal ballot concluded on May 03, 2024 subsequently his designation changed from Non-Executive Independent Director to Chairman and Non-Executive Independent Director, with effect from Friday, June 20, 2025.

2. Mr. Naveenakumar Kunjaru was appointed as Managing Director and Chairman of the Company w.e.f. June 13, 2023 and his designation changed from Chairman and Managing Director to Managing Director, with effect from Friday, June 20, 2025

3. Ms. Sneha Khemka is appointed as Company Secretary & Compliance Officer of the Company, with effect from Saturday, February 01, 2025.

4. Mrs. Sakshi Chopra resigned from the position of Company Secretary & Compliance Officer of the Company, with effect from Saturday, January 31, 2025.

5. Ms. Urmi Shah resigned from the position of Company Secretary & Compliance Officer of the Company, with effect from Thursday, August 29, 2024.

DIRECTORS RESPONSIBILITY STATEMENT:

Pursuant to Section 134(5) of the Act, the Board of Directors, to the best of their knowledge and ability, confirm that:

- In the preparation of the annual accounts, the applicable accounting standards have been followed along with proper explanation relating to material departures.

- The Directors have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent to give a true and fair view of the state of affairs of the company at the end of the financial year and of the profit and loss of the company for that period.

- The Directors have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities.

- The Directors have prepared the annual accounts on a going concern basis.

- The Directors have laid down proper Internal Financial Controls ("IFC") and such IFC are adequate and were operating effectively.

- The Directors have devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

MEETING OF BOARD OF DIRECTORS:

During the year under review, the board of directors met 14 (Fourteen) times i.e. on May 30, 2024, June 19, 2024, August 12, 2024, August 29, 2024, September 02, 2024, October 29, 2024, November 13, 2024, December 16, 2024, December 23, 2024, December 27, 2024, January 02, 2025, February 01, 2025, February 13, 2025 and February 25, 2025.

Directors attendance in Board Meetings held during the financial year and last Annual General Meeting are as under:

Name of Director	Number of Board Meetings
	Held during their tenure in FY	Attended during their tenure in FY	Attendance in the last AGM
Dr. Lalitkumar Anande	14	14	Yes
Mr. Naveenakumar Kunjaru	14	14	Yes
Mr. Gavadu Patil	14	14	Yes
Ms. Pallavi Mittal	14	2	No
Ms. Vishakha Jadhav	14	14	Yes

DETAILS OF THE COMMITTEE:

Audit Committee:

The Audit Committee is constituted in accordance with the provisions of Regulation 18 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Section 177 of The Companies Act, 2013. The Company has in place a qualified and independent Audit Committee. The role of the Audit Committee includes the powers as stipulated in LODR read with Section 177 of the Act.

During the year under review, audit committee met 7 (Seven) times. Details of composition, committee meetings and attendance of members are as follows:

	Meeting Dates
Name of Director	Nature of Membership	30.05.24	12.08.24	29.08.24	02.09.24	13.11.24	13.02.25	25.02.25
Lalitkumar Anande	Chairman	yes	yes	yes	yes	yes	yes	yes
Gavadu Patil	Member	yes	yes	yes	yes	yes	yes	yes
Vishakha Jadhav	Member	yes	yes	yes	yes	yes	yes	yes

Stakeholders Relationship Committee:

The Stakeholder Relationship Committee is constituted in accordance with the provisions of Regulation 20 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Section 178 of the Act. The role of the Stakeholders Relationship Committee includes the powers as stipulated in LODR read with Section 178 of the Act.

During the year under review, Stakeholder Relationship Committee met 7 (Seven) times. Details of composition, committee meetings and attendance of members are as follows:

	Meeting Dates
Name of Director	Nature of Membership	30.05.24	12.08.24	13.11.24	16.12.24	27.12.24	02.01.25	13.02.25
Lalitkumar Anande	Chairman	yes	yes	yes	yes	yes	yes	yes
Gavadu Patil	Member	yes	yes	yes	yes	yes	yes	yes
Vishakha Jadhav	Member	yes	yes	yes	yes	yes	yes	yes

Nomination and Remuneration Committee:

The Nomination and Remuneration Committee is constituted in compliance with the requirements under Regulation 19 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Section 178 of the Act.

During the year under review, Nomination and Remuneration committee met 2 (Two) times. Details of composition, committee meetings and attendance of members are as follows:

Name of Director	Nature of Membership	29.08.24	Meeting Dates 01.02.25
Lalitkumar Anande	Chairman	yes	yes
Vishakha Jadhav	Member	yes	yes
Gavadu Patil	Member	yes	yes

COMPANYS POLICY ON APPOINTMENT AND REMUNERATION OF DIRECTORS:

Company has been following well laid down policy on appointment and remuneration of Directors, KMP and Senior Management Personnel. The appointments of Directors are made pursuant to the recommendation of Nomination and Remuneration Committee.

The remuneration of Executive Directors comprises of Basic Salary and Perquisites and follows applicable requirements of the Companies Act, 2013. Approval of shareholders and the Central Government, if so required, for payment of remuneration to Executive Directors is sought, from time to time.

BOARDS EVALUATION:

The Board of Directors has carried out an annual evaluation of its own performance, board committees, and individual directors pursuant to the provisions of the Act and SEBI LODR. In a separate meeting of Independent Directors, performance of Non-Independent directors, the Board as a whole and Chairman of the Company was evaluated, taking into account the views of executive directors and non-executive directors. Performance evaluation of independent directors was done by the entire Board, excluding the independent director being evaluated.

DECLARATION BY INDEPENDENT DIRECTORS:

The company has received declarations from all the Independent Directors of the Company confirming that they meet the criteria of independence as prescribed under section 149 (7) of the Companies Act, 2013 and Regulation 16(1) (b) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

AUDITORS AND THEIR REPORTS:

Statutory Auditor:

M/s. Bakliwal & Co., Chartered Accountants (FRN: 130381W) were appointed as Statutory Auditors of the Company at the AGM held on Friday, September 27, 2024 for the period of 05 (Five) years from the conclusion of that AGM till the AGM to be conducted in the year of 2029. The Auditors Report issued by M/s. Bakliwal & Co., Chartered Accountants does not contain any qualification, reservation or adverse remark and the Notes on financial statement referred to in the Auditors Report are self-explanatory and do not call for any further comments.

Further M/s. Bakliwal & Co., Chartered Accountants (FRN: 130381W), vide their letter dated 14th August 2025 have resigned from the post of Statutory Auditor of the Company due to preoccupation with other professional commitments.

Secretarial Auditor:

Pursuant to the provisions of Section 204 of the Act read with the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, the Secretarial Audit for the year ended March 31, 2025 was carried out by the Secretarial Auditors, M/s. Megha Khandelwal & Associates, Practicing Company Secretaries (PR No: 4023/2023). The Report of the Secretarial Audit is annexed herewith marked as Annexure 6 to this Report.

The Secretarial Auditor has not made any adverse comments or given any qualification, reservation or adverse remarks or disclaimer in their Audit Report.

Internal Auditor:

Pursuant to provisions of Section 138 of the Companies Act, 2013 your Company appointed M/s. K S G C & Associates, Chartered Accountants (FRN: 021829C) as an Internal Auditor of the Company for FY 2025-2026. To maintain their objectivity and independence, the Internal Auditor reports to the Chairman of the Audit Committee.

Cost Auditor and Cost Audit Report:

Provisions of Section 148 of the Companies Act, 2013 read with the Companies (Cost Records and Audit) Amendment Rules, 2014 related to appointment of Cost Auditor and Cost Audit Report are not applicable to the Company.

FRAUD REPORTING BY AUDITOR:

During the year under review, the Statutory Auditor and the Secretarial Auditor have not reported any instances of frauds committed by the Company by its officers or employees to the audit committee under section 143(12) of the Companies Act, 2013, details of which needs to be mentioned in the Annual Report.

PARTICULARS OF LOAN, GUARANTEE & INVESTMENTS:

During the year under review, the Company has not given any loans or guarantees to any person. Further, the Company does not have any investment falling within the preview of Section 186 of the Act.

TRANSFER OF UNCLAIMED DIVIDEND TO INVESTOR EDUCATION AND PROTECTION FUND:

No amount of unclaimed dividend has been transferred to Investor Education and Protection Fund.

DISCLOSURE OF PENDING CASES:

There were no non-compliances by the Company and no instances of penalties and structures imposed on the Company by the Stock Exchanges or SEBI or any other statutory authority on any matter related to the capital market during the last three years.

PREVENTION ON INSIDER TRADING:

The Company has adopted a Code of Conduct for Prevention of Insider Trading with a view to regulate trading in securities by the Directors and designated employees of the Company. The Code requires pre-clearance for dealing in the Companys shares and prohibits the purchase or sale of Company shares by the Directors and the designated employees while in possession of unpublished price sensitive information in relation to the Company and during the period when the Trading Window is closed. The Board is responsible for implementation of the Code.

RISK MANAGEMENT

Your Company has a well-defined risk management framework in place. The risk management framework works at various levels across the enterprise. These levels form the strategic defense cover of the Companys risk management. The Company has a robust organizational structure for managing and reporting on risks.

WHISTLE BLOWER POLICY/ VIGIL MECHANISM:

As per the provisions of Section 177 of the Companies Act, 2013 read with regulation 22 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, a vigil mechanism has been implemented through the adoption of Whistle blower Policy with an objective to enable any employees or director, raise genuine concern or report that may constitute: Instances of corporate fraud; unethical conduct; a violation of Central or State laws, rules, regulations and/or any other regulatory or judicial directives. It also provides safeguards against victimization of employees who avail the mechanism and allows direct access to the chairman of the Audit Committee.

PREVENTION OF SEXUAL HARASSMENT AT WORKPLACE:

The Company has in place an Anti-Sexual Harassment Policy in line with the requirements of the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013. All employees (permanent, contractual, temporary, trainees) are covered under this policy. The policy is gender neutral.

During the year under the review no complaints with allegations of sexual harassment was received by the Company.

DETAILS ON MATERNITY BENEFITS:

During the year under review, no maternity benefits have been availed by any of the employee.

INTERNAL FINANCIAL CONTROL:

The Board of Directors confirms that the company has laid down set of standard processes and structure which enables to implement internal financial controls across the organization with reference to Financial Statements and that such control is adequate and are operating effectively. During the year under review, no material or serious observation has been observed for inefficiently or inadequacy of such controls.

INVESTOR RELATIONS:

The Company continuously strives for excellence in its investor relations. Company believes in building a relationship of mutual understanding with Investors. Company ensures that critical information about the Company is available to all the Investors by uploading all such information on the Companys website.

SECRETARIAL STANDARDS:

The Company is in compliance with the Secretarial Standards on Meetings of the Board of Directors (SS 1) and General Meetings (SS 2) issued by the Institute of Company Secretaries of India.

EMPLOYEE STOCK OPTION SCHEME:

The Company has introduced Aayush Wellness Limited - Employee Stock Option Plan 2024 (AWL - ESOP 2024) for the eligible employees of the Company and its future subsidiary, if any. The (AWL - ESOP 2024) was approved by the Board of Directors on June 19, 2024 and subsequently by the members of the Company through Postal Ballot on July 23, 2024. The Company also got in-principle approval from exchange on letter dated October 17, 2024.

OTHER DISCLOSURES:

During the year, no corporate insolvency resolution process was initiated under the Insolvency and Bankruptcy Code, 2016, either by or against the Company, before NCLT or other court(s).

MATERIAL CHANGES IN THE COMPANY: -

- Change of Name:

Name of the company is changed from Aayush Food and Herbs Limited to Aayush Wellness Limited with effect from June 18, 2024.

- Change of Registered office:

The Board of Directors at their meeting held on January 02, 2025 approved shifting of the registered office of the company within local limits i.e. From 55, 2nd Floor, Lane 2, Westend Marg, Saidullajab, Near Saket Metro Station, New Delhi, Delhi 110030 To 275, Ground Floor, West End Marg, Near Saket Metro Station Exit: 2, New Delhi-110030.

- Incorporation of Wholly owned subsidiaries

Following Companies incorporated as wholly owned subsidiaries (WOS):

Sr. No.	Name of Company	Relationship	Change	Effective Date
1.	AAYUSH HEALTHSCIENCES PRIVATE LIMITED	WOS	Incorporated	November 07, 2024
2.	AAYUSH WORLDWIDE PRIVATE LIMITED	WOS	Incorporated	January 04, 2024
3.	AAYUSH LABS PRIVATE LIMITED	WOS	Incorporated	August 26, 2025
4.	AAYUSH VENTURES PRIVATE LIMITED	WOS	Incorporated	August 27, 2025

- Launches Herbal Pan Masala:

Aayush Wellness has introduced Herbal Pan Masala to revolutionize the chewing habits of Indias 27.49 crore tobacco consumers. With rising awareness and growing health consciousness, the product offers a safer and Herbal alternative that mimics the taste of traditional pan masala without harmful effects. This innovation positions the company into the Indias massive Rs. 46,682 Cr pan masala market, enabling access to a large consumer base while contributing to the broader shift towards wellness-focused products.

- Enter the Nutraceutical Market with Sleep Gummies:

Aayush Wellness has entered the USD 23.8 billion nutraceutical market with the launch of its premium offering, Dreamy Sleep Gummies, designed to enhance sleep quality and address sleep disorders. This strategic entry underscores the companys commitment to innovation and excellence in wellness, positioning it to capture value in a rapidly expanding sector driven by rising health awareness and lifestyle-related challenges.

- Launches Beauty Gummies:

Aayush Wellness Limited has entered the USD 14.9 billion beauty and personal care market with the introduction of its Beauty Vitamin Gummies. Crafted to provide a comprehensive solution for individuals struggling to maintain their natural beauty due to poor diet and nutritional deficiencies, this innovation bridges the gap between wellness and personal care. By addressing the growing consumer demand for convenient and effective beauty-from-within solutions, the company strengthens its presence in the evolving nutraceutical and cosmeceutical landscape.

- Introduces Rs. 10/- Herbal Pan Masala Sachet:

Building on the strong response to its Herbal Pan Masala, the company has introduced a small sachet priced at 10 to empower the economically weaker sections of society seeking to move away from harmful tobacco consumption. This inclusive initiative not only supports healthier lifestyle choices but also enables the company to expand its distribution network across country and capture greater value within Indias massive pan masala market.

- Aayush Health Centre:

Aayush Wellness has installed a health ATM that shall conduct a wide range of diagnostics tests, in 2-3 minutes, maintain digital health records, and also facilitate Telemedicine to address health deficiencies before they become critical.

The health ATM shall be able to conduct an up to 59 test including blood test, sugar test, Urine test, Haemoglobin test, skin test, eye test, cancer risk test, Lipid Profile test, and other basic health checkups, at a very affordable price.

Further, the health ATM shall also facilitate Telemedicine, maintain Digital Health Records, Cloud connectivity generates smart reports and integration with Ayushman Bharat Digital Mission to benefit majority of the Indian Population.

ACKNOWLEDGEMENT:

The Board of Directors acknowledges and places on record their sincere appreciation to all stakeholders, customers, vendors, banks, Central and State Governments and all other individual directly or indirectly associated with the Company for their continued co-operation and excellent support received from them.

The Board also wishes to place on record its appreciation to the esteemed investors for showing their confidence and faith in the management of the Company. Your directors recognize and appreciate the efforts and hard work of all the employees of the Company and their continued contribution to promote its development.

By order of Board of Directors
For Aayush Wellness Limited
(Formerly known as Aayush Food and Herbs Limited)
Sd/-	Sd/-
Lalitkumar Anande	Naveenakumar Kunjaru
Chairman & Director	Managing Director	Place: New Delhi
DIN: 02953124	DIN: 07087891	Date: September 04, 2025